Using high-throughput sequencing to investigate the gene expression profile data of patients with lung adenocarcinoma complicated with pulmonary embolism and pulmonary embolism. Bioinformatics was used to mine the common signal pathway of patients with lung adenocarcinoma complicated with pulmonary embolism and pulmonary embolism to screen the differentially expressed mRNAs between the two contrast groups.

The peripheral blood of patients with lung adenocarcinoma complicated with pulmonary embolism, lung adenocarcinoma, pulmonary embolism and healthy subjects (4 cases in each group , with a total of 16 cases) were collected from the Affiliated Tumor Hospital of Xinjiang Medical University from January to December 2019. The gene expression profile data sets of 16 cases in the group were constructed by RNA sequencing. One data set is the gene expression profile data of lung adenocarcinoma with pulmonary embolism group and lung adenocarcinoma group, and the other is the gene expression data of pulmonary embolism group and healthy control group. The differentially expressed genes of the two data sets were screened by R language, and the common differential mRNA of the two contrast groups was screened by the intersection of the two data sets by Excel software.The functional clustering and enriched signal pathways of the two contrast groups were screened by GO analysis and kyoto encyclopedia of genes and genomes (KEGG) signal pathway analysis.

There were 14 common differentially expressed mRNAs between lung adenocarcinoma complicated with pulmonary embolism group and pulmonary embolism group and between pulmonary embolism group and healthy control group, of which including 10 up-regulated mRNAs and 4 down-regulated mRNAs. The most significantly down-regulated mRNA was solute carrier family 9 member 3 (SLC9A3). The GO analysis showed that the two contrast groups were related to cellular biological process, complement response and inflammatory response. The KEGG pathway analysis showed that the common enriched pathways in the two contrast groups included complement and coagulation cascade, systemic lupus erythematosus, rheumatoid arthritis, nuclear factor-κB (NF-κB) signal pathway and so on.

The SLC9A3 may be used as a biomarker of lung adenocarcinoma with pulmonary embolism. The occurrence of pulmonary embolism in lung adenocarcinoma may be related to complement response, inflammatory response and other molecular functions, and may also be related to complement and coagulation cascade, systemic lupus erythematosus, rheumatoid arthritis, nuclear factor-κB (NF-κB) signal pathway and so on.

Lung adenocarcinoma; Pulmonary embolism; RNA sequencing; Gene expression profile; Differentially expressed genes; Venous thromboembolism